



# CDRH Executive Briefing

---

David W. Feigal, Jr., M.D., M.P.H.

Director

Center for Devices and Radiological Health

*Washington, DC October 4, 1999*

# Overview

- ▶ FDAMA
- ▶ Regulations
- ▶ Reengineering
- ▶ Cross-cutting Activities
- ▶ Resources
- ▶ Alternatives in 510(k)s, MDRs
- ▶ Harmonization

# FDAMA Accomplishments

## Year Two



- ▶ Stakeholders meeting, live video teleconference
- ▶ Report to Congress, “Designing a Medical Device Surveillance Network” Draft guidance
- ▶ Updated lists
  - Devices for third party review
  - Recognized consensus standards

# FDAMA Accomplishments

## Year Two



- ▶ Draft guidance
  - Resolving scientific disputes
  - Least burdensome means to market
  
- ▶ Updated guidance
  - FAQ on consensus standards
  - Amended panel procedures
  - Device tracking

# Regulations Published in '99



62 regulations published in CY '99 so far

- ▶ 7 final rules
- ▶ 3 Direct to Final Rules
- ▶ 11 Proposed Rules
- ▶ 38 Notices
- ▶ 3 Advanced Notice of Public Rule Making (ANPR)

# Reengineering

## Examples of Reengineered Process

- ▶ New 510(k) paradigm
- ▶ Regulations development
- ▶ Recalls
- ▶ GMP inspections
- ▶ Products development protocol (PDP)
- ▶ Modular PMA review
- ▶ Standards

# Reengineering

## New Projects

- ▶ Postmarket process
- ▶ Registration and listing
- ▶ QSIT and HACCP
- ▶ Class I recalls
- ▶ Radiological health
- ▶ Bioresearch monitoring



# Cross-cutting Issues

## Staff from many offices work together

- ▶ Immediate problem - Ad hoc committee
  - Evaluates, follows issue from several perspectives
  - Safety Alert, Public Health Advisory
  - Forum for industry, medical community, consumers & gov't to work on solution together
- ▶ Standing committee on one type of device
  - Follows, coordinates activities across Center
  - Works on solutions to specific problems as above

# CDRH FTE History

Fiscal Years 1976 - 1999\*




Med. Dev. Amend.

Merger of BRH & BMD


SMDA MQSA

FDAMA

# CDRH FTE Distribution



**FY95**  
**N=1,109**



**FY98**  
**N=1,037**

# Resources Are Shrinking

- ▶ Flat line budgets have meant actual decrease in funds available for program.
- ▶ CDRH down 113 FTEs since FY 1996; includes 45 positions cut in last fiscal year.
- ▶ FDAMA added new responsibilities without funding.
- ▶ International activities are costly.

# Resources Are Shrinking

- ▶ Workload complexity is increasing.
- ▶ Review timeframes are still too long (e.g., PMAs – 12.4 months total elapsed time).
- ▶ Administration's FY 2000 budget does not request additional premarket resources.
- ▶ Congressional budget includes targeted increases and an unfunded pay-raise

# Shrinking Resources: Re-engineering

## Mechanisms:

- ▶ 510(k) Changes
- ▶ Modular PMA
- ▶ 3<sup>rd</sup> party review
- ▶ MDR Summary reporting

# 510(k)s - Alternatives

	Applications Received (4-98 to 9-99)	Review Complete	Average Review Time
Abbreviated	105	82	91
Special	458	411	28
Traditional	6147	6453	110

# 510(k)s - Third party review

- ▶ 154 device types eligible
  - mostly class II
- ▶ same device types = 1200 510(k)s / yr
- ▶ only 32 510(k)s submitted to 3rd parties so far this fiscal year
- ▶ Average total review time for comparable 510(k)s -- same product code & fiscal year:
  - 3rd party - 57 days
  - All FDA review - 105 days


# Summary Reporting of MDRs

Goal: Reduce “noise” in the MDR system, improve the signal to noise ratio

- ▶ Allow periodic submission of well-known, repetitive reports in line item format
- ▶ Expect 38,000 summary reports in FY ‘99
- ▶ 45 manufacturers participating
- ▶ 52 exemptions
- ▶ New system in place for January 2000

# Manufacturer Reports

(Includes Summary Reporting)



# Global Harmonization



7th meeting on June 27-July 1, 1999  
Hosted by the U.S.

[Http://www.fda.gov/cdrh/harmmain.html](http://www.fda.gov/cdrh/harmmain.html)

# CDRH: The Future

Transparent  
Adequately Resourced  
Re-engineered  
FDAMA-ed  
Science Based  
Partners  
Credibility

▶ “Yours and Ours”

# Our Website:

[www.fda.gov/cdrh](http://www.fda.gov/cdrh)